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Abstract
Background: Serum CA125 is routinely used in the follow up of ovarian cancer. The objective of the present study
was to evaluate the usefulness of CA125 in the detection of ovarian cancer recurrence.
Methods: This retrospective case study was carried out at a tertiary gynaecological cancer centre in Australia.
Patients with all cell types of epithelial ovarian cancer (EOC) treated between 2003 and2010 were considered
eligible. We excluded patients whose aim of treatment was palliative, had no follow-up, had no pre-operative
CA125 reading or had pre-operative CA125 levels < 35 U/mL. After primary treatment, patients were followed up
as per guidelines suggested by National Comprehensive Cancer Network (NCCN). We recorded if symptoms,
findings from physical examination, imaging or serum CA125 levels led to the diagnosis of recurrence. An increase
in CA125 levels to twice the postoperative nadir was considered as “doubling” at any time during follow up.
Results: Analysis is based on 56 patients who completed primary treatment and who presented for a total of 274
follow-up episodes. Of those, 29 patients (52%) developed a recurrence within the follow up period. Recurrence
was diagnosed by CA125 alone in 14 of 29 patients (48%). CA125 was not elevated in 7 patients (24%) who
recurred. Doubling of CA125 from nadir was observed in 27/29 patients. Of those 27 patients the doubling from
nadir occurred within the normal range of 35 U/ml in 3 cases and outside the normal range in 24 cases.
Multivariate analysis suggests that doubling of serum CA125 (OR 5.10, p 0.036) and nadir CA125 > 10 U/ml (OR
2.86, p 0.01) remained the only independent factors to predict ovarian cancer recurrence.
Conclusions: The present paper proposes the validation of a novel CA125 algorithm aiming to detect recurrent
EOC. These data may allow us to investigate novel ways of follow up that do not require a patient’s physical
attendance at a clinic (virtual follow-up).
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Background
World-wide more than 200,000 women are diagnosed
with ovarian cancer annually [1]. Due to the lack of
effective screening methods, the majority of patients are
diagnosed at stages 3 or 4, thus implying poor prognosis
[2]. Standard treatment includes a combination of sur-
gery plus chemotherapy and once primary treatment is
completed patients are followed regularly. Recurrences
following primary treatment are common. The National
Comprehensive Cancer Network (NCCN) guidelines
suggest that patients are seen every two to four months
for two years, every three to six months for another
three years and annually thereafter [3]. At every visit the
guidelines recommend a physical examination including
a pelvic exam and a tumour marker test if the marker
was elevated prior to initial treatment. Medical imaging
and other blood tests are recommended only when clini-
cally indicated.
In contrast to worldwide current clinical practice of
seeing patients for regular follow up for many years, the
evidence to support follow up of ovarian cancer patients
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and have physical examinations as well as a brief history
a n db l o o dt e s t sa sw e l la si m a ging regularly. If patients
would not need to attend a follow up visit physically,
they could be managed through new, virtual strategies.
Blood tests, medical imaging and a patient’sh i s t o r y
could be taken remotely without the need of the
patient’s physical presence.
CA125 has an established role as a serum tumour
marker to triage patients with pelvic masses and has
been advocated to predict chemotherapy response in
advanced ovarian cancer [6]. Recently we suggested that
preoperative serum CA125 is a marker to predict survi-
val in surgical stage 1 EOC [7] and in ovarian tumours
of low malignant potential (borderline tumours) (Tang
et al., in press, Gynecologic Oncology). Finally, serum
CA125 has a long established role in the follow up of
patients with EOC [8].
The primary objective of the present study was to
evaluate the usefulness of routine serum CA125 levels
in the detection of ovarian cancer recurrence.
Methods
This retrospective case study was carried out at a ter-
tiary gynaecological cancer centre in Queensland, Aus-
tralia. All the participating patients had surgery with
one surgeon (AO) who is a certified gynaecological
oncologist (CGO) accredited through the Royal Austra-
lian and New Zealand College for Obstetrics and Gynae-
cology. All patients had provided consent for their data
to be used for research purposes. Consecutive patients
with all cell types of invasive epithelial ovarian cancer
(EOC) treated between 2003 and 2010 were considered
eligible (n = 127). Patients with tumours of low malig-
nant potential and with non-epithelial ovarian cancer
were not considered eligible. We excluded patients
whose aim of treatment was palliative (n = 10) rather
than curative or because of a lack of follow-up (n = 39).
Patients with no pre-operative CA125 levels (n = 3) or
those with pre-operative CA125 levels < 35 U/mL were
excluded (n = 18). Patients were eligible to be included
if their pre-treatment CA125 levels were elevated (≥ 35
U/mL). IRB approval was not required for this retro-
spective study.
Following primary treatment, patients were seen every
3 months for three years and 6-monthly for another two
years. At each follow-up visit a brief history of symp-
toms, a physical examination and a serum CA125 level
have been obtained. Physical examination included pal-
pation for enlarged groin and supra-clavicular lymph
nodes, external abdominal examination and a pelvic
examination, which consisted of a speculum visual
examination, bimanual vaginal examination, and a rectal
examination. Medical imaging was not performed regu-
larly but was only performed when clinically indicated.
Statistical methods: Descriptive statistics were used to
present baseline characteristics. Our primary outcome
was disease-free survival and was calculated from the
date of commencement of initial treatment to the date
of recurrence. For the aim of this analysis, patients were
censored at the date of their last follow up visit or on
the date when recurrence was diagnosed. Variables eval-
uated as predictors of recurrence include age, stage of
the disease, grade, residual disease, cell type, nadir levels
of CA125 (categorised as ≤ 10 and > 10) and CA125
levels at follow-up. All variables that showed a p-value <
0.1 on univariate analyses were included in Cox propor-
tional hazards models. CA125 levels were evaluated as a
categorical variable coded as 0 if there was no doubling
of CA125 and coded as ‘1’ if CA125 levels doubled over
the period of follow-up. Stata for windows (version 11.2)
was used for statistical analyses.
We recorded if symptoms, findings from physical
examination, imaging or serum CA125 levels led to the
diagnosis of recurrence. Recurrence has been confirmed
histologically or cytologically whenever possible through
a fine needle aspirate. In 2 patients recurrence was diag-
nosed through a laparoscopic investigative procedure
and was confirmed histologically. A systematic second
look operation was not performed. If histological confir-
mation of recurrence was not possible, the diagnosis of
recurrence was made by imaging. An increase in CA125
levels to twice the postoperative nadir was considered as
“doubling” at any time during follow up [9]. If a serum
CA125 increased to less than double the nadir, it was
repeated in 4 to 8 weeks.
Results
Analysis is based on 56 patients who had primary sur-
gery and completed chemotherapy as part of their pri-
mary treatment and who presented for a total of 274
follow-up episodes. Median follow up was 28.9 months
(95% CI: 18-67.2).
Patients’ baseline characteristics are shown in Table 1.
In brief, 45 patients (80%) had stage 3 or 4 disease and
29 patients (52%) developed a recurrence within the fol-
low up period. Recurrence was diagnosed by serial
CA125 measurements alone in 14 of 29 patients (48%).
A diagnosis of recurrence was established in 7 patients
(24%) when CA125 was not involved.
Of the 29 patients with recurrence, a doubling in
CA125 from nadir was observed in 27 patients, whereas
in two patients CA125 did not double. Of those 27
patients the doubling from nadir occurred within the
normal range of 35 U/ml in 3 cases and outside the nor-
mal range in 24 cases. In one additional patient the
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also diagnosed with recurrence thereafter.
Of all 56 patients, a doubling from nadir was observed
in 37 patients. From those 37 patients, doubling outside
the normal range of 35 U/ml occurred in 25 patients
and all of these patients were diagnosed with recurrence.
Doubling from nadir within the normal range (≤ 35 U/
ml) occurred in 12 patients and three of those patients
were diagnosed with recurrence subsequently.
Doubling of CA125, advanced stage of the disease, ser-
ous cell type, and a nadir CA125 levels higher than 10
U/ml showed significant associations with recurrence in
univariate analysis (Table 2). Of these covariates, only a
nadir CA125 levels higher than 10 U/ml and doubling
of CA125 predicted recurrences in multivariate models
(Table 3).
Discussion
Our study supports the hypothesis that doubling of
serum CA125 and a nadir CA125 > 10 U/ml after com-
pletion of first line treatment are associated with a sig-
nificantly increased risk of recurrence. Patients with
EOC whose serum CA125 was elevated but dropped to
normal levels after initial treatment and who experi-
enced a doubling of CA125 relative to her nadir, are at
very high risk of developing a recurrence.
Current NCCN guidelines for the follow up of patients
with EOC are widely accepted but only limited evidence
is available to support current clinical practice [3].
There are no clinical trials available to determine opti-
mal follow up intervals, sequence or duration of follow
up.
A limited number of retrospective publications
address the issue of the method by which ovarian cancer
recurrence is detected. A series of 80 patients from
Hong Kong suggested that 42 patients (52.5%) had posi-
tive findings on physical examination. However, in none
of those, positive physical examination finding was the
first sign of recurrence. Overall, 73 patients (91%) had
raised CA125 at the time of recurrence[4]. A series from
Israel including 69 patients with 43 recurrences sug-
gested that abnormal findings from physical examination
yielded a sensitivity rate of only 34.9% [5]. The diagnosis
of recurrence was based on an abnormal physical exami-
nation alone in only 2 (4.6%) patients. Both studies
Table 1 Baseline characteristics of Patients included in
this study
Characteristic Values
Age, mean (SD) [years] 62.2 (10.8)
Pre-op CA125, median (IQR) 305 (136-894)
FIGO stages (3 or 4), n (%) 45 (80.4)
No residual disease, n (%) 29 (51.8)
Surgical procedures, n (%)
Salpingo oophorectomy 54 (96.4)
Omentectomy 49 (87.5)
Pelvic Lymph node dissection 45 (80.4)
Hysterectomy 41 (73.2)
Aortic Lymph node dissection 39 (69.6)
Appendicectomy 26 (46.4)
Rectal resection 13 (23.2)
Liver/Spleen resection 5 (8.9)
Vaginectomy 5 (8.9)
Small bowel resection 4 (7.1)
Diaphragm 3 (5.4)
Ureter 3 (5.4)
Others* 8 (14.3)
Cell type
Serous, n (%) 36 (64.3)
Other, n (%) 20 (35.7)
Grade, n (%)
1 4 (7.1)
2 14 (25.0)
3 38 (67.9)
Relapse, n (%) 29 (51.8)
Relapse, detected by, n (%)
CA125 alone 14 (48.3)
CA125 plus any other (imaging, clinical) 8 (27.6)
CA125 not elevated 7 (24.1)
*Abdominal wall resection; thoracoscopic surgery; hernia repair; distal
pancreatectomy; hemicolectomy; large bowel resection.
Table 2 Univariate association of prognostic factors with
recurrence
Variable HR 95% CI P
Age 0.97 0.94 1.01 0.150
CA125 doubling 6.19 1.47 26.12 0.013
CA125 nadir > 10 U/ml 2.92 1.36 6.27 0.006
FIGO stages 3 or 4 5.50 1.30 23.30 0.021
Cell type (serous vs. other) 2.79 1.13 6.89 0.026
Grade 1 Referent
Grade 2 vs. 1 0.60 0.12 3.13 0.544
Grade 3 vs. 1 1.25 0.29 5.38 0.763
Residual disease (any vs. nil) 1.93 0.92 4.05 0.083
Nadir levels > 10 U/ml 2.92 1.36 6.27 0.006
Table 3 Multivariate Cox proportional hazards model
predicting recurrence
Variables HR 95% CI P
CA125 doubling 5.10 1.11 23.43 0.036
FIGO stages 3 or 4 vs stage 1 or 2 1.52 0.28 8.30 0.629
Nadir CA125 levels > 10 U/ml 2.86 1.29 6.37 0.010
Residual disease (any vs. nil) 1.06 0.48 2.33 0.893
Cell type (serous vs. other) 1.52 0.55 4.15 0.417
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low up for EOC. A study by Fehm et al. suggested that
CA125 had the highest sensitivity to detect ovarian can-
cer recurrence, followed by medical imaging and physi-
cal examination [10]. In an Italian series including 331
asymptomatic ovarian cancer patients with recurrent
EOC, CA125 alone or in combination with medical ima-
ging detected 58% of all recurrences [11]. More recent
studies explore the value of serial PET-CT examinations
for the detection of recurrent EOC but PET-CT may
n o tb ea v a i l a b l et ot h em a j o r i t yo fw o m e no rt ow o m e n
in non-metropolitan areas.
In three of the above studies, CA125 was considered
elevated if it exceeded the upper limit of normal
[ 4 , 5 , 1 0 ] .T h eI t a l i a ns e r i e sc o n s i d e r e da ne l e v a t e d
CA125 if CA125 doubled from the upper limit of nor-
mal or if there was a doubling of CA125 from the nadir
if CA125 levels were persistently elevated [11]. A study
by Crawford et al. using data from 79 patients, showed
that CA125 within normal ranges carries prognostic
information for survival outcomes [12]. Similarly, the
prognostic role of CA125 has been shown in multi-
centric studies [13,14].
The present series suggests that a doubling of serum
CA125 from its nadir is highly and strongly predictive
for recurrence even if the CA125 level is still within the
upper limit of normal. Our series included 29 recur-
rences and in 27/29 patients a doubling of CA125 from
nadir was observed. Three of these patients doubled
their CA125 within the normal range of CA125 (≤ 35
U/ml). Another patient diagnosed with recurrence
increased her CA125 1.9-fold (from 11 U/ml to 21 U/
ml) and missed the criteria of doubling. Our data sug-
gest that extending the criteria of “doubled CA125 even
within the normal CA125 range” might potentially
increase the detection of recurrences by 11% to 15%.
While health care professionals and patients agree that
follow up is important, their expectations differ. Patients
accept inconvenience, costs and physical discomfort
associated with regular physical examinations hoping
that recurrent disease is detected at an early stage when
the tumour load is small and still amenable for curative
treatment [15,16]. In contrast, clinicians feel that physi-
cal examinations are unlikely to result in survival bene-
fits for patients [8]. Health care professionals’
expectations to follow up include the monitoring of
symptoms associated with previous treatment or relapse
[15,16] and quality assurance.
Potentially, these findings could have an impact on the
service provision for ovarian cancer patients. While evi-
dence suggests that patients with ovarian cancer benefit
from specialised gynaecological oncology input for rea-
sons mentioned above, a significant percentage of ovar-
ian cancer patients are still not referred to specialised
services in large parts of the world. Providing virtual fol-
low up to patients might overcome a geographical bar-
rier, make follow up services available and attractive to
patients in non-metropolitan areas at low cost and make
management by gynaecological oncology specialist more
attractive.
Given the small sample size, we acknowledge that this
s t u d yi so n l yh y p o t h e s i s - g e n e r a t i n g .W ep l a nt oe x t e n d
our sample size and in order to validate these findings.
Conclusions
In contrast to poor evidence form retrospective or
observational studies, consensus exists amongst both,
patients and health care providers that follow up is
important. The present paper proposes the validation of
a novel CA125 algorithm aiming to detect recurrent
EOC. These data may allow us to investigate novel ways
of follow up that do not require a patient’sp h y s i c a l
attendance at a clinic.
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